World Library  
Flag as Inappropriate
Email this Article
 

Renovo plc

Renovo Group plc
Type Public limited company
(LSE: RNVO)
Headquarters Manchester, United Kingdom
Key people Mark Ferguson (CEO)
Website www.renovo.com

Renovo Group plc (LSE: RNVO) is a biopharmaceutical company, which was founded in 1998 and is headquartered in Manchester, United Kingdom. It works in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.[1] Renovo does not currently have any marketed products. It aims "to be first to market with a scar prevention pharmaceutical drug in the US and Europe"[2] in approximately 2014. As of 2011, it employs 10 people, although it once employed over 100.[3]

Renovo is listed on the London Stock Exchange and is a constituent of the FTSE Fledgling Index.

Contents

  • Products 1
  • 2 Disambiguation
  • References 3
  • External links 4

Products

Renovo does not currently have any marketed products. Its development pipeline currently includes one drug in phase III clinical development, two drugs in phase II clinical development, and numerous pre-clinical candidates.[4]

Drug Phase Action
Juvista Failed[5] Injected to the wound margins around the time of surgery causes a prevention or reduction of scarring through introduction of recombinant TGFβ3.
Adaprev Halted[6] Injected at the time of surgery for the prevention and reduction of scarring and adhesions between the tendon and surrounding tissues following tendon repair.].
Prevascar Halted[7] Injected to the wound margins around the time of surgery causes a reduction of scarring through suppression of TGFβ1 and TGFβ2.
Juvidex Renovo plans to partner Juvidex as a cosmetic ingredient for the improvement of skin appearance and to promote the healing of damaged skin.
RN1005 Phase I Clinical trial RN1005 is an advanced preclinical candidate pharmaceutical, discovered by Renovo, targeting the Wnt pathway to reduce scarring and enhance tissue regeneration.

Disambiguation

Renovo Group, PLC. has no affiliation with Renovo Neural, Inc. (www.renovoneural.com), a preclinical research organization founded in Cleveland, OH, USA, in 2008. Renovo Neural's business is focused on identifying and developing neural therapies for neurodegenerative diseases, including multiple sclerosis and Parkinson's Disease. [8]

References

  1. ^ London Regenerative Medicine Network – January 2007 Meeting
  2. ^ http://www.renovo.com
  3. ^ Pharma Times Just 10% of workforce left at Renovo after Juvista failure (4 March 2011). Pharmatimes.com.
  4. ^ Renovo – Products
  5. ^ ''Pharma Times'' Just 10% of workforce left at Renovo after Juvista failure (4 March 2011). Pharmatimes.com.
  6. ^ Ashcroft, Jamie. (18 November 2011) ''ProactiveInvestors'' – Renovo ends Adaprev development (18 November 2011). Proactiveinvestors.co.uk.
  7. ^ Ashcroft, Jamie. (16 April 2012) ''ProactiveInvestor'' Renovo ends Prevascar development (16 April 2012). Proactiveinvestors.co.uk.
  8. ^ Renovo Neural's founder sets industry standard for multiple sclerosis

External links

  • www.renovo.com


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.